Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Few Clouds On High-Priced, Ultra-Orphan Drug Horizon

Fri, 04/28/2017 - 6:36pm

With BioMarin's Brineura hitting the market with a $702,000 annual price tag, recent experience for other high-priced rare disease drugs...

      Related Stories 

BioMarin Expects 30% Markdown For Orphan Pediatric Drug Brineura

Fri, 04/28/2017 - 6:34pm

Fast US approval of ultra-rare pediatric disease drug Brineura (cerliponase alfa), with an annual list price of $702,000, is a...

      Related Stories 

After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three

Fri, 04/28/2017 - 5:59pm

With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total...

      Related Stories 

Q1 Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva

Fri, 04/28/2017 - 4:20pm

Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes...

      Related Stories 

Hep B Cure May Lie In Reducing Surface Antigen

Fri, 04/28/2017 - 2:20pm

Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination...

      Related Stories 

Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q

Fri, 04/28/2017 - 9:01am

Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on...

      Related Stories 

Kiadis Aims To Boost Stem Cell Transplant Market With Adjuvant Filing

Fri, 04/28/2017 - 2:55am

Kiadis Pharma hopes to tap into a $1bn-plus commercial opportunity with its lead product ATIR101 in the treatment of blood...

      Related Stories 

VIDEO: BioInvent CEO On Pfizer Immunotherapy Alliance

Fri, 04/28/2017 - 12:52am

Three years after setting out to turnaround BioInvent, company president & CEO Michael Oredsson explains how the company is developing...

      Related Stories 

Novartis Slapped With New $49m Fine For Korea ‘Rebates’

Thu, 04/27/2017 - 5:41pm

Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number...

      Related Stories 

Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

Thu, 04/27/2017 - 3:45pm

Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance...

      Related Stories 

Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline

Thu, 04/27/2017 - 3:09pm

AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab...

      Related Stories 

Roche Delivers Strong Quarter On Ocrevus Launch, Pipeline Promise

Thu, 04/27/2017 - 1:15pm

Roche's strong first quarter and promising array of innovative medicines left investors wondering why it didn't also lift its financial...

      Related Stories 

Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib

Thu, 04/27/2017 - 8:02am

Bayer has initiated the regulatory filing process in the US for its pipeline non-Hodgkin's lymphoma drug copanlisib, head of pharma...

      Related Stories 

VIDEO: Market-ready Advicenne Seeks Partners and €40m VC Funds

Thu, 04/27/2017 - 1:16am

With a focus on pediatric neurology and nephrology, Dr Luc-André Granier, founder, CEO and medical director of the 10-year old...

      Related Stories 

Glenmark Readying Xolair Biosimilar Challenge

Thu, 04/27/2017 - 1:06am

Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair...

      Related Stories 

Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance

Wed, 04/26/2017 - 10:31pm

Amgen reported a surprising double-digit decline for Enbrel during the first quarter and sales for the cholesterol-lowering biologic Repatha showed...

      Related Stories 

ASLAN Firms Up IPO Plans As Lead Asset Progresses

Wed, 04/26/2017 - 9:54pm

Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering...

      Related Stories 

GSK's Walmsley Focused On Upcoming Launches Amid 'Uncertain' Times

Wed, 04/26/2017 - 2:49pm

New CEO confirmed GSK's commitment to maintaining its three business unit structure ‒ "as long as all three businesses continue...

      Related Stories 

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Wed, 04/26/2017 - 2:22pm

Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly...

      Related Stories